A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 AS SINGLE-AGENT AND COMBINATION THERAPY IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS

Brief description of study

This is a research study where doctors are testing a new medicine called XB002 to see if it's safe to take for patients and effective for treating advanced solid tumors in patients. They're doing it in two parts:

First, they're trying different amounts of XB002 to find the highest dose that doesn't cause too many side effects. Then, the study team is going to use that dosage to see how well the medicine works when given alone or with other drugs like nivolumab or bevacizumab.

The study team will also collecting samples from patients to understand more about how the treatment is working. Patients will get XB002 through an IV every three weeks until their doctors decide to stop. They'll check in every 12 weeks to see how they're doing.


Clinical Study Identifier: s22-00793
Principal Investigator: Kristen Spencer.
Other Investigators: Nila Theresa De La Rosa, Joshua K Sabari, Nina Beri, Carol M Lee, Salman Rafi Punekar, Elaine Shum, Jessica Wang, Jonathan B Kahn, Scot Niglio, Keriann M Scavone, Kathleen M Madden, David R. Wise, Janice Mehnert, Douglas K Marks.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.